相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
Angelika Kaczynska et al.
BREAST CANCER (2017)
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
Seung Min Kim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes
Brett T. Staahl et al.
NATURE BIOTECHNOLOGY (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Delivery technologies for genome editing
Hao Yin et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
CRISPR/Cas9: Transcending the Reality of Genome Editing
Sergiu Chira et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier
Peng Wang et al.
ADVANCED SCIENCE (2017)
Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles
Zeming Chen et al.
ADVANCED FUNCTIONAL MATERIALS (2017)
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma
Chao Liang et al.
BIOMATERIALS (2017)
One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs
Erwei Zuo et al.
CELL RESEARCH (2017)
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges
Rubul Mout et al.
BIOCONJUGATE CHEMISTRY (2017)
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
M. Martin et al.
ANNALS OF ONCOLOGY (2016)
An overview of the effective combination therapies for the treatment of breast cancer
Cristina Nunez et al.
BIOMATERIALS (2016)
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Naoto T. Ueno et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS
Ruohan Zhang et al.
CANCER BIOLOGY & THERAPY (2016)
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Zahi Mitri et al.
CLINICAL CANCER RESEARCH (2016)
MicroRNA-34a and its Target Genes: Key Factors in Cancer Multidrug Resistance
Morteza Ghandadi et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer
Tommaso De Marchi et al.
DRUG DISCOVERY TODAY (2016)
CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: apersonalized molecular surgical therapy
Huibin Tang et al.
EMBO MOLECULAR MEDICINE (2016)
Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
Gil Awada et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Ixabepilone for the treatment of endometrial cancer
Claudia Marchetti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
In Vivo Delivery Systems for Therapeutic Genome Editing
Luyao Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles
Nazli Erdogar et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Maximilian Haeussler et al.
JOURNAL OF GENETICS AND GENOMICS (2016)
miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance
Merve Mutlu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
Sergio Ruiz et al.
MOLECULAR CELL (2016)
The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA
Ines Fonfara et al.
NATURE (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Xueda Hu et al.
TRENDS IN GENETICS (2016)
Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis
Q. Xu et al.
CELL DEATH & DISEASE (2016)
Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption
Jong Seong Ha et al.
SCIENTIFIC REPORTS (2016)
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
Raffaella Palumbo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
10-Hydroxycamptothecin induces apoptosis in human neuroblastoma SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways
Z. F. Yuan et al.
NEOPLASMA (2016)
Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy
Peng Zhang et al.
BIOMATERIALS (2015)
Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds
Jesse G. Zalatan et al.
CELL (2015)
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Bernd Zetsche et al.
CELL (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
Molecular aspects of breast cancer resistance to drugs (Review)
Gloria M. Calaf et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Analysis of different HER-2 mutations in breast cancer progression and drug resistance
Zijia Sun et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Elena Geretti et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Benjamin P. Kleinstiver et al.
NATURE (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Benjamin P. Kleinstiver et al.
NATURE BIOTECHNOLOGY (2015)
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Junwei Shi et al.
NATURE BIOTECHNOLOGY (2015)
Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display
David M. Shechner et al.
NATURE METHODS (2015)
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Puping Liang et al.
PROTEIN & CELL (2015)
Raloxifene Induces Autophagy-Dependent Cell Death in Breast Cancer Cells via the Activation of AMP-Activated Protein Kinase
Dong Eun Kim et al.
MOLECULES AND CELLS (2015)
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Lukasz Swiech et al.
NATURE BIOTECHNOLOGY (2015)
Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines
Tsui-Ting Ho et al.
NUCLEIC ACIDS RESEARCH (2015)
A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression
Linghe Xi et al.
GENOME BIOLOGY (2015)
Applications of the CRISPR-Cas9 system in cancer biology
Francisco J. Sanchez-Rivera et al.
NATURE REVIEWS CANCER (2015)
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Qiong Wu et al.
CANCER LETTERS (2014)
Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA
Hiroshi Nishimasu et al.
CELL (2014)
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Luke A. Gilbert et al.
CELL (2014)
Development and Applications of CRISPR-Cas9 for Genome Engineering
Patrick D. Hsu et al.
CELL (2014)
Toremifene for Breast Cancer: A Review of 20 Years of Data
Charles L. Vogel et al.
CLINICAL BREAST CANCER (2014)
ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER plus breast cancer
Mary M. Heckler et al.
FEBS JOURNAL (2014)
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
Seung Woo Cho et al.
GENOME RESEARCH (2014)
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
Yuexin Zhou et al.
NATURE (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Hao Yin et al.
NATURE BIOTECHNOLOGY (2014)
Comprehensive analysis of the specificity of transcription activator-like effector nucleases
Alexandre Juillerat et al.
NUCLEIC ACIDS RESEARCH (2014)
CCNA2 Is a Prognostic Biomarker for ER plus Breast Cancer and Tamoxifen Resistance
Tian Gao et al.
PLOS ONE (2014)
MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers
Morassa Mohseni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Genetic Screens in Human Cells Using the CRISPR-Cas9 System
Tim Wang et al.
SCIENCE (2014)
Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation
Martin Jinek et al.
SCIENCE (2014)
Functional significance of long non-coding RNAs in breast cancer
Rajeev Vikram et al.
BREAST CANCER (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
Hyo Jin Kang et al.
SCIENTIFIC REPORTS (2014)
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer
Felicity E. B. May
CANCER MANAGEMENT AND RESEARCH (2014)
Toremifene in the treatment of breast cancer
Mika V. J. Mustonen et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Association between common risk factors and molecular subtypes in breast cancer patients
Fatma P. Turkoz et al.
BREAST (2013)
Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System
Baohui Chen et al.
CELL (2013)
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Luke A. Gilbert et al.
CELL (2013)
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system
Albert W. Cheng et al.
CELL RESEARCH (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Optical control of mammalian endogenous transcription and epigenetic states
Silvana Konermann et al.
NATURE (2013)
DNA targeting specificity of RNA-guided Cas9 nucleases
Patrick D. Hsu et al.
NATURE BIOTECHNOLOGY (2013)
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Pablo Perez-Pinera et al.
NATURE METHODS (2013)
CRISPR RNA-guided activation of endogenous human genes
Morgan L. Maeder et al.
NATURE METHODS (2013)
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
Kevin M. Esvelt et al.
NATURE METHODS (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
J. T. Ribeiro et al.
ANNALS OF ONCOLOGY (2012)
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®
Maria Ait-Tihyaty et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
Giuseppe Curigliano
CANCER TREATMENT REVIEWS (2012)
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
Ahmad Awada et al.
CANCER TREATMENT REVIEWS (2012)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Sidong Huang et al.
CELL (2012)
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2012)
Chemotherapy-Resistant Metastatic Breast Cancer
Carrie Marquette et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2012)
Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines
Dingding Wang et al.
MOLECULAR MEDICINE REPORTS (2012)
Two Hundred Years of Cancer Research
Vincent T. DeVita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
Suzanne E. Wardell et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
Murray J. Towle et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A public genome-scale lentiviral expression library of human ORFs
Xiaoping Yang et al.
NATURE METHODS (2011)
Mastering RNAi in mice
Louisa Flintoft
NATURE REVIEWS GENETICS (2011)
Evolution and classification of the CRISPR-Cas systems
Kira S. Makarova et al.
NATURE REVIEWS MICROBIOLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
Patrick J. Grohar et al.
NEOPLASIA (2011)
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Rajnish A. Gupta et al.
NATURE (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression
Michael S. Cunnington et al.
PLOS GENETICS (2010)
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Trevor Hay et al.
CANCER RESEARCH (2009)
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Kwok-K. Wong et al.
CLINICAL CANCER RESEARCH (2009)
Long non-coding RNAs: insights into functions
Tim R. Mercer et al.
NATURE REVIEWS GENETICS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
New therapeutic options for chemotherapy-resistant metastatic breast cancer
Paolo Pronzato
DRUGS (2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Tatiana Okouneva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Rapid Open-Source engineering of customized zinc-finger nucleases for highly efficient gene modification
Morgan L. Maeder et al.
MOLECULAR CELL (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Maximizing mouse cancer models
Kristopher K. Frese et al.
NATURE REVIEWS CANCER (2007)
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences
Julianne Smith et al.
NUCLEIC ACIDS RESEARCH (2006)
ERBB2 kinase domain mutation in the lung squamous cell carcinoma
Jong Woo Lee et al.
CANCER LETTERS (2006)
The transcriptional landscape of the mammalian genome
P Carninci et al.
SCIENCE (2005)
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
FD Urnov et al.
NATURE (2005)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Docetaxel - A review of its use in metastatic breast cancer
KA Lyseng-Williamson et al.
DRUGS (2005)
New insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer
R Schiff et al.
BREAST CANCER RESEARCH (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
The role of glutathione in cancer
GK Balendiran et al.
CELL BIOCHEMISTRY AND FUNCTION (2004)
Sources of estrogen and their importance
ER Simpson
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics
PTR Rajagopalan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Bleomycin: New perspectives on the mechanism of action
SM Hecht
JOURNAL OF NATURAL PRODUCTS (2000)
分享论文
